Investigator Clinical Trial for Evaluation of Safety and Tolerability After Transplantation of Fetal Mesencephalic Dopamine Neuronal Precursor Cells in Patients With Parkinson's Disease
This study is phase I/II clinical trials which is accessible to those involved in the study
and conducted by only Bundang CHA hospital.
The progress of the clinical trails is reported to and evaluated by Data monitoring
committee before the enrolment of next human subject.
Interventional
Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
Presence or absence of cancer foramtion and infection
If not included in the following criteria, the cells are are considered to be safe and tolerable. Cells with grade 3 or more in NCI grading system Cells contaminated with infectious materials Cells with risk of cancer formation
5 years
Yes
Sang Sup Chung, M.D., Ph.D.
Principal Investigator
CHA Bundang Medical center, CHA university
Korea: Institutional Review Board
PBC09-074
NCT01860794
May 2013
February 2018
Name | Location |
---|